DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effectiveness of Imiquimod 3.75% Topical Cream Compared to Vanos Cream 0.1% in Subjects With Early Stage Cutaneous T-cell Lymphoma

Information source: University of Rochester
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Mycosis Fungoides

Intervention: 3.75% Imiquimod Cream (Drug); 0.1% Fluocinonide Cream (Drug)

Phase: N/A

Status: Not yet recruiting

Sponsored by: University of Rochester

Official(s) and/or principal investigator(s):
Brian Poligone, M.D. Ph.D., Principal Investigator, Affiliation: University of Rochester Department of Dermatology

Overall contact:
Carolina V Alexander Rodriguez, B.S., Phone: 585-489-2883, Email: carolina_alexander@urmc.rochester.edu


This study is being conducted by the Department of Dermatology at the University of Rochester. The purpose of this study is to determine safety, effectiveness, and tolerability of two topical therapies, imiquimod and fluocinonide, for patients with early stage Cutaneous T-cell Lymphoma (CTCL).

Clinical Details

Official title: Feasibility Study to Determine Effectiveness of 3.75% Topical Imiquimod Cream and Topical Vanos (Fluocinonide) Cream 0.1% in the Treatment of Early Stage Cutaneous T-cell Lymphoma

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Response Rate between baseline and week 16

Secondary outcome:

Response Rate 24 and 52 weeks after baseline

Change (%) in Physician Global Assessment between baseline and week 16

Safety and tolerabiliy of Imiquimod in patients with CTCL (adverse events)

Learn about T cell dysregulation in the skin from patients with CTCL (Using left over tissue from biopsies)

Detailed description: The purpose of the study is to compare the safety, effectiveness, and tolerability of two topical therapies, imiquimod and fluocinonide, for patients with early stage CTCL.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: 1. Male and female subjects aged ≥18 years. 2. Willing and able to give informed consent 3. Diagnosis of Mycosis Fungoides In cases with equivocal histological features, the diagnosis may be confirmed through the use of clonal T-cell gamma gene rearrangement, as detected by PCR amplification and primer sets specific for the T-cell receptor gamma chain genes. 4. Subjects must have at least one target lesion 5. Subjects will be able to comply with the study instructions, apply the study medication as directed and attend all visits. 6. Females of child-bearing potential must have a negative urine pregnancy test before randomization and must agree to use an adequate method of contraception (abstinence, condoms, hormonal therapy, barrier methods) during the study. 7. Patients must be otherwise healthy with an ECOG Performance status of 0 or 1. 8. The patient must not have had topical (2 weeks) or systemic therapy (4 weeks), radiotherapy (4 weeks) or phototherapy therapy (4 weeks) for Mycosis Fungoides within the stated number of weeks prior to start of treatment. 9. Eligible patients will be those who topical corticosteroid would be a preferred treatment and include patients newly diagnosed with stage IA, IB, or IIA disease, or those patients currently stable on therapy, in whom topical corticosteroids are being newly added to the regimen (i. e. recurrence or resistant lesions not currently treated with topical corticosteroids) Exclusion Criteria: To be eligible for inclusion in this study the subjects must not meet any of the following criteria: 1. Female who is pregnant, nursing an infant, or planning a pregnancy during the study period. 2. Have concomitant dermatologic or medical condition(s) which may interfere with the investigator's ability to evaluate the subject's response to the study drug. 3. Received any investigational drug or taking part in any clinical study within one month prior to this study. 4. Known reaction or allergy to test drug or excipient. 5. Presence of major medical illness or symptoms of a clinically significant illness that may influence the study. 6. Have any reason which, in the opinion of the investigator, interferes with the ability of the subject to participate in or complete the trial, or which places the subject at undue risk such as a history of drug, alcohol or other substance abuse or other factors limiting the ability to co-operate and to comply with this protocol. 7. Lesions on the genitals, axillae and face will not be selected for study treatment and evaluation.

Locations and Contacts

Carolina V Alexander Rodriguez, B.S., Phone: 585-489-2883, Email: carolina_alexander@urmc.rochester.edu

Additional Information

Starting date: December 2014
Last updated: December 1, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017